| Property | Value |
|---|
|
?:abstract
|
-
INTRODUCTION: The pandemic of SARS CoV-2 has required urgent medical treatments for numerous patients. As no specific antiviral agents were available, different off-the-shelf alternatives have been explored. OBJECTIVE: Here, we review the rationale behind the use of Favipiravir, and report of the specific studies supporting this treatment being conducted. METHODS: Here we analyze the relevant literature to conclude about the present opportunities offered by this therapeutic agent. RESULTS: This antiviral drug approved influenza in Japan since 2014, has a demonstrated in vitro activity against SARS CoV-2 and is being investigated in several trials for SARS CoV-2. Signals of benefit were shown in a small trial for SARS CoV-2. However, in another small study, there was no advantage. CONCLUSIONS: Further studies, statistically more significant, are urgently needed to understand the best opportunities offered by this treatment.
|
|
?:creator
|
|
|
?:doi
|
-
10.1007/s43440-020-00175-2
|
|
?:doi
|
|
|
?:journal
|
|
|
?:license
|
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/57c60c73a1ff7320e655bddcf9b12ce296e5ece3.json
|
|
?:pmc_json_files
|
-
document_parses/pmc_json/PMC7590246.xml.json
|
|
?:pmcid
|
|
|
?:pmid
|
|
|
?:pmid
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
?:sha_id
|
|
|
?:source
|
|
|
?:title
|
-
Favipiravir use for SARS CoV-2 infection
|
|
?:type
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}